PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Flavoxate hydrochloride - Overactive bladder (adults)
PAD Profile : Flavoxate hydrochloride - Overactive bladder (adults)
Keywords :
antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics
Brand Names Include :
Urispas
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section.
05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Flavoxate is non-formulary.
Solifenacin is the 1st line treatment option.
Tolterodine immediate release tablets or Trospium are 2nd line options in patients for whom solifenacin is not suitable.
05 February 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Flavoxate is not recommended for treating overactive bladder in line with NICE NG123 - guidance can be found below
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence